Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD40 | P25942 | 2/20 | 0.46 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | CHRND | Q07001 | 6/20 | 0.44 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.44 |
| ▸ | CHRNG | P07510 | 2/20 | 0.44 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.44 |
| ▸ | NPY4R | P50391 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2183888 | 0.88 | CD40 (0.51) | CD40OPRD1OPRM1OPRK1CHRND | |
| SCHEMBL2193850 | 0.84 | NPY4R (0.58) | NPY4R | |
| SCHEMBL2191389 | 0.83 | NPY4R (0.55) | IL23RNPY4R | |
| SCHEMBL2183041 | 0.82 | NPY4R (0.43) | CHRNDNPY4R | |
| SCHEMBL2192841 | 0.82 | NPY4R (0.60) | NPY4R | |
| SCHEMBL31619564 | 0.81 | NPY4R (0.57) | NPY4R | |
| SCHEMBL29707515 | 0.81 | NPY1R (0.56) | NPY4R | |
| SCHEMBL29589142 | 0.81 | NPY1R (0.59) | NPY4R | |
| SCHEMBL29511610 | 0.81 | NPY1R (0.56) | NPY4R | |
| SCHEMBL16468664 | 0.80 | NPY4R (0.52) | CHRNDCHRNA1CHRNGCHRNB1NPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680263-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | CD40 2429/4885IL23R 2709/4885OPRD1 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.